Washington University School of Medicine, St. Louis, MO, USA.
J Vasc Surg. 2011 Aug;54(2):307-315.e1. doi: 10.1016/j.jvs.2010.12.058. Epub 2011 Mar 2.
The Zenith Renu abdominal aortic aneurysm (AAA) Ancillary Graft (Cook Medical Inc, Bloomington, Ind) provides active proximal fixation for treatment of pre-existing endografts with failed or failing proximal fixation or seal. The purpose of this study was to evaluate the midterm outcomes of treatment with this device.
From September 2005 to November 2006, a prospective, nonrandomized, multicenter, postmarket registry was utilized to collect physician experiences from 151 cases (89 converters and 62 main body extensions) at 95 institutions. Preoperative indications and procedural and postimplantation outcomes were collected and analyzed. Technical success and clinical success were determined as defined by the Society of Vascular Surgery reporting standards.
Patients were predominantly male (87%) with a mean age of 77 years. The interval between the original endograft implantation to Renu treatment was 43.4 ± 18.7 months. The indications for treatment were endoleak (n = 111), migration (n = 136), or both (n = 94). Technical success was 98.0% with two cases of intraoperative conversion and one case of persistent type IA endoleak. The median follow-up for the cohort was 45.0 months (range, 0-56 months; interquartile range, 25.0 months). Overall, 32 cases had treatment failures that included at least one of the following: death (n = 5), type I/III endoleak (n = 18), graft infection (n = 1), thrombosis (n = 1), aneurysm enlargement >5 mm (n = 9), rupture (n = 4), conversion (n = 9, with 7 after 30 days), and migration (n = 1). Overall, the clinical success for the entire cohort during the follow-up period was 78.8% (119/151).
The postmarket registry data confirm that the Zenith Renu AAA Ancillary Graft can be used to treat endovascular repairs that failed due to proximal attachment failures. The salvage treatment with the Renu device had high technical success rate and resulted in clinical success in a majority of patients (78.8%). While failed endovascular repairs can be salvaged, a clinical failure in one of five patients still emphasizes the importance of patient and device selection during initial endovascular aneurysm repair to ensure durable success.
Zenith Renu 腹主动脉瘤(AAA)辅助移植物(库克医疗公司,布卢明顿,印第安纳州)为治疗先前存在的内移植物提供主动近端固定,这些内移植物存在近端固定或密封失败或失效。本研究的目的是评估该装置的中期结果。
2005 年 9 月至 2006 年 11 月,利用前瞻性、非随机、多中心、上市后注册的方式,在 95 个机构中收集了 151 例病例(89 例转换和 62 例主体延伸)的医生经验。收集并分析了术前指征、手术过程和植入后结果。技术成功和临床成功的定义按照血管外科学会的报告标准。
患者主要为男性(87%),平均年龄 77 岁。Zenith Renu 治疗与原始内移植物植入之间的间隔为 43.4±18.7 个月。治疗的适应证为内漏(n=111)、迁移(n=136)或两者兼有(n=94)。技术成功率为 98.0%,有 2 例术中转换和 1 例持续性 1A 型内漏。该队列的中位随访时间为 45.0 个月(范围,0-56 个月;四分位距,25.0 个月)。总的来说,有 32 例治疗失败,包括以下至少一种情况:死亡(n=5)、1 型/3 型内漏(n=18)、移植物感染(n=1)、血栓形成(n=1)、动脉瘤增大>5mm(n=9)、破裂(n=4)、转换(n=9,其中 7 例在 30 天后发生)和迁移(n=1)。总的来说,在整个随访期间,整个队列的临床成功率为 78.8%(119/151)。
上市后注册数据证实,Zenith Renu AAA 辅助移植物可用于治疗因近端固定失败而导致的血管内修复失败。使用 Renu 装置进行的挽救性治疗具有很高的技术成功率,并使大多数患者(78.8%)达到临床成功。虽然血管内修复失败可以挽救,但在 5 例患者中仍有 1 例临床失败,这仍然强调了在初始血管内动脉瘤修复过程中选择患者和装置的重要性,以确保持久的成功。